These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

752 related articles for article (PubMed ID: 28829236)

  • 1. A review of tofacitinib efficacy in rheumatoid arthritis patients who have had an inadequate response or intolerance to methotrexate.
    Fleischmann R
    Expert Opin Pharmacother; 2017 Oct; 18(14):1525-1533. PubMed ID: 28829236
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b/4, double-blind, head-to-head, randomised controlled trial.
    Fleischmann R; Mysler E; Hall S; Kivitz AJ; Moots RJ; Luo Z; DeMasi R; Soma K; Zhang R; Takiya L; Tatulych S; Mojcik C; Krishnaswami S; Menon S; Smolen JS;
    Lancet; 2017 Jul; 390(10093):457-468. PubMed ID: 28629665
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of the efficacy and safety of tofacitinib and upadacitinib in patients with active rheumatoid arthritis: A Bayesian network meta-analysis of randomized controlled trials.
    Song GG; Choi SJ; Lee YH
    Int J Rheum Dis; 2019 Aug; 22(8):1563-1571. PubMed ID: 31211506
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of Glucocorticoids on the Clinical and Radiographic Efficacy of Tofacitinib in Patients with Rheumatoid Arthritis: A Posthoc Analysis of Data from 6 Phase III Studies.
    Charles-Schoeman C; van der Heijde D; Burmester GR; Nash P; Zerbini CAF; Connell CA; Fan H; Kwok K; Bananis E; Fleischmann R
    J Rheumatol; 2018 Feb; 45(2):177-187. PubMed ID: 29142036
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tofacitinib in Combination With Methotrexate in Patients With Rheumatoid Arthritis: Clinical Efficacy, Radiographic, and Safety Outcomes From a Twenty-Four-Month, Phase III Study.
    van der Heijde D; Strand V; Tanaka Y; Keystone E; Kremer J; Zerbini CAF; Cardiel MH; Cohen S; Nash P; Song YW; Tegzová D; Gruben D; Wallenstein G; Connell CA; Fleischmann R;
    Arthritis Rheumatol; 2019 Jun; 71(6):878-891. PubMed ID: 30666826
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A pooled analysis of the safety of tofacitinib as monotherapy or in combination with background conventional synthetic disease-modifying antirheumatic drugs in a Phase 3 rheumatoid arthritis population.
    Kivitz AJ; Cohen S; Keystone E; van Vollenhoven RF; Haraoui B; Kaine J; Fan H; Connell CA; Bananis E; Takiya L; Fleischmann R
    Semin Arthritis Rheum; 2018 Dec; 48(3):406-415. PubMed ID: 30177460
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of conventional synthetic disease-modifying antirheumatic drugs, glucocorticoids and tofacitinib: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis.
    Gaujoux-Viala C; Nam J; Ramiro S; Landewé R; Buch MH; Smolen JS; Gossec L
    Ann Rheum Dis; 2014 Mar; 73(3):510-5. PubMed ID: 24395555
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparing the effects of tofacitinib, methotrexate and the combination, on bone marrow oedema, synovitis and bone erosion in methotrexate-naive, early active rheumatoid arthritis: results of an exploratory randomised MRI study incorporating semiquantitative and quantitative techniques.
    Conaghan PG; Østergaard M; Bowes MA; Wu C; Fuerst T; van der Heijde D; Irazoque-Palazuelos F; Soto-Raices O; Hrycaj P; Xie Z; Zhang R; Wyman BT; Bradley JD; Soma K; Wilkinson B
    Ann Rheum Dis; 2016 Jun; 75(6):1024-33. PubMed ID: 27002108
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of tofacitinib for active rheumatoid arthritis with an inadequate response to methotrexate or disease-modifying antirheumatic drugs: a meta-analysis of randomized controlled trials.
    Song GG; Bae SC; Lee YH
    Korean J Intern Med; 2014 Sep; 29(5):656-63. PubMed ID: 25228842
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) versus placebo in combination with background methotrexate in patients with active rheumatoid arthritis and an inadequate response to methotrexate alone.
    Kremer JM; Cohen S; Wilkinson BE; Connell CA; French JL; Gomez-Reino J; Gruben D; Kanik KS; Krishnaswami S; Pascual-Ramos V; Wallenstein G; Zwillich SH
    Arthritis Rheum; 2012 Apr; 64(4):970-81. PubMed ID: 22006202
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tofacitinib in combination with nonbiologic disease-modifying antirheumatic drugs in patients with active rheumatoid arthritis: a randomized trial.
    Kremer J; Li ZG; Hall S; Fleischmann R; Genovese M; Martin-Mola E; Isaacs JD; Gruben D; Wallenstein G; Krishnaswami S; Zwillich SH; Koncz T; Riese R; Bradley J
    Ann Intern Med; 2013 Aug; 159(4):253-61. PubMed ID: 24026258
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tofacitinib, an oral Janus kinase inhibitor, for the treatment of Latin American patients with rheumatoid arthritis: Pooled efficacy and safety analyses of Phase 3 and long-term extension studies.
    Radominski SC; Cardiel MH; Citera G; Goecke A; Jaller JJ; Lomonte ABV; Miranda P; Velez P; Xibillé D; Kwok K; Rojo R; García EG
    Reumatol Clin; 2017; 13(4):201-209. PubMed ID: 27317492
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative Efficacy of JAK Inhibitors for Moderate-To-Severe Rheumatoid Arthritis: A Network Meta-Analysis.
    Pope J; Sawant R; Tundia N; Du EX; Qi CZ; Song Y; Tang P; Betts KA
    Adv Ther; 2020 May; 37(5):2356-2372. PubMed ID: 32297280
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tofacitinib, an oral Janus kinase inhibitor, in patients from Mexico with rheumatoid arthritis: Pooled efficacy and safety analyses from Phase 3 and LTE studies.
    Burgos-Vargas R; Cardiel M; Xibillé D; Pacheco-Tena C; Pascual-Ramos V; Abud-Mendoza C; Mahgoub E; Rahman M; Fan H; Rojo R; García E; Santana K
    Reumatol Clin (Engl Ed); 2019; 15(1):43-53. PubMed ID: 28552437
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tofacitinib in the treatment of moderate-to-severe rheumatoid arthritis: a cost-effectiveness analysis compared with adalimumab in Taiwan.
    Chen DY; Hsu PN; Tang CH; Claxton L; Valluri S; Gerber RA
    J Med Econ; 2019 Aug; 22(8):777-787. PubMed ID: 30982378
    [No Abstract]   [Full Text] [Related]  

  • 16. Patient-reported outcomes for tofacitinib with and without methotrexate, or adalimumab with methotrexate, in rheumatoid arthritis: a phase IIIB/IV trial.
    Strand V; Mysler E; Moots RJ; Wallenstein GV; DeMasi R; Gruben D; Soma K; Iikuni N; Smolen JS; Fleischmann R
    RMD Open; 2019; 5(2):e001040. PubMed ID: 31673419
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Systematic review of tofacitinib: a new drug for the management of rheumatoid arthritis.
    Kaur K; Kalra S; Kaushal S
    Clin Ther; 2014 Jul; 36(7):1074-86. PubMed ID: 25047498
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical efficacy of launched JAK inhibitors in rheumatoid arthritis.
    Taylor PC
    Rheumatology (Oxford); 2019 Feb; 58(Suppl 1):i17-i26. PubMed ID: 30806707
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of tofacitinib in Japanese patients with rheumatoid arthritis by background methotrexate dose: A post hoc analysis of clinical trial data.
    Takeuchi T; Yamanaka H; Yamaoka K; Arai S; Toyoizumi S; DeMasi R; Fukuma Y; Hirose T; Sugiyama N; Zwillich SH; Tanaka Y
    Mod Rheumatol; 2019 Sep; 29(5):756-766. PubMed ID: 30489177
    [No Abstract]   [Full Text] [Related]  

  • 20. Efficacy of tofacitinib in patients with rheumatoid arthritis stratified by background methotrexate dose group.
    Fleischmann R; Mease PJ; Schwartzman S; Hwang LJ; Soma K; Connell CA; Takiya L; Bananis E
    Clin Rheumatol; 2017 Jan; 36(1):15-24. PubMed ID: 27734232
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 38.